News

Geospiza has received a phase I SBIR grant for ‘Software Systems for Detecting Rare Mutations’ from the National Human Genome Research Institute (1R43HG005297-01). Reportedly, this project will focus

Wyatt Technology has reported that Pfizer has chosen its DAWN HELEOS Multi-Angle Light Scattering (MALS) instrument to monitor protein reagent quality in drug discovery. Reportedly, the instrument’s analytical

Merz Pharmaceuticals (Merz) has reported that its NT 201, botulinum toxin type A free from complexing proteins (also known as Xeomin in Europe and Canada), was more efficacious

FDA has provided a complete response letter to Genzyme regarding its supplemental New Drug Application for Clolar (clofarabine) in previously untreated older adult patients with acute myeloid leukemia

Perrigo has received final approval from the FDA for its Abbreviated New Drug Application for over-the-counter Polyethylene Glycol 3350, Powder for Solution. Perrigo is expecting to begin shipping

Sandoz has launched its recombinant human growth hormone somatropin in Japan. The launch follows the precedent-setting approval of somatropin – marketed as Omnitrope in the EU, the US,

Vantia Therapeutics has reported that its novel oral small molecule drug for the treatment of dysmenorrhoea (painful menstruation) has entered phase II proof-of-concept trials. In addition, the company

Imedicor has signed an agreement with Dallas-based Access Pharmaceuticals for the North American commercial launch of MuGard, its FDA-approved oral wound rinse for the management of oral mucositis

OncoGenex has received an additional Fast Track Designation from FDA for OGX-011 (also known as custirsen sodium) for progressive metastatic prostate cancer, in combination with first-line docetaxel treatment.